Merrimack Pharmaceuticals’ stock plunged more than 32 percent after the company announced the termination of the SHERLOC Phase II clinical trial.
U.S. Food and Drug Administration Commissioner Scott Gottlieb announced that the regulatory agency is relaunching the Drug Competition Action Plan in 2019 with some additional initiatives.
Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.
In an announcement touting 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported that the company received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular risk reduction.
AbbVie Invests $100 Million in Morphic Therapeutic to Develop Integrin Inhibitors for Fibrotic Diseases
Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.
Citing structural simplification, Pfizer announced plans to cut the company’s global staffing by about 2 percent, primarily through voluntary layoffs and early retirement through the end of 2018 and early in 2019.
Eisai Co. and Purdue Pharma L.P. announced top-line results from the companies’ SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
San Mateo, Calif.-based startup CuraSen Therapeutics surged forward with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.
Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much larger via a four-company merger. Ann Dover, Discovery’s founder, president and CEO, spoke with BioSpace about the merger and biobank’s new identity.
Sanofi is reportedly eying a significant expansion in Cambridge, Mass., that could spur a hiring spree. In Portland, Oregon, Genentech is looking to open an office space that would require up to 300 new hires, The Portland Business Journal reported.
Watertown, Mass.-based SQZ Biotechnologies could be on the receiving end of up to $1 billion following the company’s signing of an expansion agreement with pharma giant Roche.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee voted to recommend AcelRx Pharmaceuticals’ Dsuvia to manage moderate-to-severe pain.
Emeryville, Calif.-based Berkeley Lights closed on a $95 million financing round, led by Nikon.
Forbes’ 2018 ranking of the “World’s Best Employers” includes a number of global biopharmaceutical companies.
Researchers at Johns Hopkins University, the University of California, San Diego (UCSD), and the National Institute of Mental Health grew retinas in Petri dishes and discovered fundamental factors involved in the development of vision and color vision.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.
In 2014, the U.S. National Institutes of Health launched a program called the Undiagnosed Disease Network. The New England Journal of Medicine published a study looking at the results of the network.
The U.S. Food and Drug Administration lifted a clinical hold and accepted an Investigational New Drug Application (IND) for an experimental sickle cell disease treatment being jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with Novartis’ experimental humanized anti-P-selectin monoclonal antibody crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.